Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416563 | 0.96 | S1PR1 (0.65) | S1PR1S1PR3CYP2D6CD274ALDH1A1 | |
| SCHEMBL2475133 | 0.92 | S1PR1 (0.66) | S1PR1S1PR3CYP2D6CD274 | |
| SCHEMBL2449636 | 0.90 | S1PR1 (0.53) | S1PR1S1PR3CYP2D6CD274ALDH1A1 | |
| SCHEMBL2411301 | 0.90 | S1PR1 (0.73) | S1PR1S1PR3CYP2D6 | |
| SCHEMBL2412762 | 0.89 | S1PR1 (0.66) | S1PR1S1PR3CYP2D6CD274 | |
| SCHEMBL14481927 | 0.89 | S1PR1 (0.66) | S1PR1S1PR3CYP2D6CD274 | |
| SCHEMBL14482303 | 0.85 | S1PR1 (0.69) | S1PR1S1PR3CYP2D6 | |
| SCHEMBL2408965 | 0.84 | S1PR1 (0.74) | S1PR1S1PR3CYP2D6 | |
| SCHEMBL1293177 | 0.83 | S1PR1 (0.68) | S1PR1S1PR3CD274ALDH1A1 | |
| SCHEMBL1293006 | 0.83 | S1PR1 (0.68) | S1PR1S1PR3CD274ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547662-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2013-01-23 | — | — | EP | claimed |
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | US | claimed |
| WO-2011113309-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-09-22 | — | — | WO | claimed |
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885CYP2D6 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.